Zynerba Pharmaceuticals, Inc. – NASDAQ:ZYNE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Zynerba Pharmaceuticals stock price monthly change
-1.51%
month
Zynerba Pharmaceuticals stock price quarterly change
+290.16%
quarter
Zynerba Pharmaceuticals stock price yearly change
+85.77%
year
Zynerba Pharmaceuticals key metrics
Market Cap | 70.12M |
Enterprise value | N/A |
P/E | -0.54 |
EV/Sales | N/A |
EV/EBITDA | 0.61 |
Price/Sales | N/A |
Price/Book | 0.38 |
PEG ratio | -0.03 |
EPS | -0.78 |
Revenue | N/A |
EBITDA | -38.28M |
Income | -37.00M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZynerba Pharmaceuticals stock price history
Zynerba Pharmaceuticals stock forecast
Zynerba Pharmaceuticals financial statements
| Sep 2022 | 0 | -8.85M | |
|---|---|---|---|
| Dec 2022 | 0 | -7.61M | |
| Mar 2023 | 0 | -9.75M | |
| Jun 2023 | 0 | -10.77M |
| 2023-05-15 | -0.19 | -0.21 |
|---|
| Sep 2022 | 62366738 | 9.60M | 15.41% |
|---|---|---|---|
| Dec 2022 | 55520894 | 9.29M | 16.74% |
| Mar 2023 | 48636533 | 9.66M | 19.88% |
| Jun 2023 | 40476561 | 11.45M | 28.3% |
| Sep 2022 | -9.65M | -95.09K | 3.19M |
|---|---|---|---|
| Dec 2022 | -5.68M | -7.4K | 399.35K |
| Mar 2023 | -7.88M | -89.55K | 1.72M |
| Jun 2023 | -8.41M | -8.39K | -6.70K |
Zynerba Pharmaceuticals alternative data
| Aug 2023 | 25 |
|---|---|
| Sep 2023 | 25 |
| Oct 2023 | 25 |
| Nov 2023 | 25 |
| Dec 2023 | 25 |
| Jan 2024 | 25 |
| Feb 2024 | 25 |
| Mar 2024 | 25 |
| Apr 2024 | 25 |
| May 2024 | 25 |
| Jun 2024 | 25 |
| Jul 2024 | 25 |
Zynerba Pharmaceuticals other data
27.24%
-3.15%
of ZYNE is owned by hedge funds
10.97M
-952.15K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 0 | 90546 |
| Feb 2023 | 0 | 3173 |
| Jun 2023 | 0 | 690 |
| Sep 2023 | 0 | 48145 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SEBREE TERRI B officer: President | Common Stock | 12,401 | $1.33 | $16,444 | ||
Sale | SEBREE TERRI B officer: President | Common Stock | 12,401 | $1.33 | $16,444 | ||
Sale | ROSENBERGER BRIAN officer: VP, Commercial & Busin.. | Common Stock | 6,411 | $1.33 | $8,501 | ||
Sale | FICKENSCHER JAMES E officer: Chief Fi.. | Common Stock | 8,998 | $1.33 | $11,931 | ||
Sale | FICKENSCHER JAMES E officer: Chief Fi.. | Common Stock | 8,998 | $1.33 | $11,931 | ||
Sale | JONES KENNETH T officer: See Remarks | Common Stock | 2,505 | $1.33 | $3,322 | ||
Sale | ANIDO ARMANDO director, officer: Chairman & C.. | Common Stock | 17,830 | $1.33 | $23,643 | ||
Sale | STEPHENSON PAMELA director | Common Stock | 115 | $0.35 | $40 | ||
Sale | MOCH KENNETH I director | Common Stock | 115 | $0.35 | $40 | ||
Sale | KISNER DANIEL L director | Common Stock | 115 | $0.35 | $40 |
| Patent |
|---|
Application Filling date: 17 Mar 2022 Issue date: 14 Jul 2022 |
Application PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME Filling date: 24 Nov 2021 Issue date: 23 Jun 2022 |
Application Filling date: 2 Sep 2021 Issue date: 31 Mar 2022 |
Application Filling date: 28 Jun 2021 Issue date: 30 Dec 2021 |
Application Filling date: 25 May 2021 Issue date: 2 Dec 2021 |
Application Filling date: 16 Sep 2020 Issue date: 18 Mar 2021 |
Application PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME Filling date: 28 Aug 2020 Issue date: 18 Feb 2021 |
Application Filling date: 18 Aug 2020 Issue date: 4 Feb 2021 |
Application Filling date: 6 Aug 2020 Issue date: 19 Nov 2020 |
Grant Filling date: 7 Oct 2019 Issue date: 1 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2018 2 Aug 2018 | Q2 2018 Earnings Call Transcript |
| Q4 2016 27 Mar 2017 | Q4 2016 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Armando Anido MBA (1958) Chairman & Chief Executive Officer | $902,080 |
| Ms. Terri B. Sebree (1958) Pres | $686,790 |
| Mr. James E. Fickenscher (1964) Chief Financial Officer, Vice President of Corporation Devel. & Treasurer | $582,820 |
-
When is Zynerba Pharmaceuticals's next earnings date?
Unfortunately, Zynerba Pharmaceuticals's (ZYNE) next earnings date is currently unknown.
-
Does Zynerba Pharmaceuticals pay dividends?
No, Zynerba Pharmaceuticals does not pay dividends.
-
How much money does Zynerba Pharmaceuticals make?
Zynerba Pharmaceuticals has a market capitalization of 70.12M. Zynerba Pharmaceuticals made a loss 34.82M US dollars in net income (profit) last year or -$0.21 on an earnings per share basis.
-
What is Zynerba Pharmaceuticals's stock symbol?
Zynerba Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ZYNE".
-
What is Zynerba Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Zynerba Pharmaceuticals?
Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Zynerba Pharmaceuticals's key executives?
Zynerba Pharmaceuticals's management team includes the following people:
- Mr. Armando Anido MBA Chairman & Chief Executive Officer(age: 67, pay: $902,080)
- Ms. Terri B. Sebree Pres(age: 67, pay: $686,790)
- Mr. James E. Fickenscher Chief Financial Officer, Vice President of Corporation Devel. & Treasurer(age: 61, pay: $582,820)
-
How many employees does Zynerba Pharmaceuticals have?
As Jul 2024, Zynerba Pharmaceuticals employs 25 workers.
-
When Zynerba Pharmaceuticals went public?
Zynerba Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 5 Aug 2015.
-
What is Zynerba Pharmaceuticals's official website?
The official website for Zynerba Pharmaceuticals is zynerba.com.
-
Where are Zynerba Pharmaceuticals's headquarters?
Zynerba Pharmaceuticals is headquartered at 80 West Lancaster Avenue, Devon, PA.
-
How can i contact Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals's mailing address is 80 West Lancaster Avenue, Devon, PA and company can be reached via phone at +48 45817505.
Zynerba Pharmaceuticals company profile:
Zynerba Pharmaceuticals, Inc.
zynerba.comExchange:
NASDAQ
Full time employees:
25
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
80 West Lancaster Avenue
Devon, PA 19333
Devon, PA 19333
CIK: 0001621443
ISIN: US98986X1090
CUSIP: 98986X109
